Report Detail

Request for Sample of this report

Pharma & Healthcare Global HER2 Targeting ADC Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

  • RnM4665674
    • |
  • 19 January, 2026
    • |
  • Global
    • |
  • 88 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global HER2 Targeting ADC Drugs market size was valued at US$ 8215 million in 2025 and is forecast to a readjusted size of US$ 14378 million by 2032 with a CAGR of 8.0% during review period.
In 2025, global HER2 Targeting ADC Drugs reached approximately 6.99 M Units, with an average global market price of around 1143 USD per Unit.
HER2 Targeting ADC Drugs (HER2-targeted antibody–drug conjugates) are a class of targeted cancer medicines that use an anti-HER2 monoclonal antibody to recognize and bind tumor cells with HER2 overexpression, amplification, or certain HER2-driven biology, and then deliver a highly potent cytotoxic payload into (and sometimes around) those cells. Structurally, they are built from three essential parts: (1) the HER2 antibody (the “homing” component), (2) a chemical linker (designed to be stable in blood but release the payload under specific conditions), and (3) the payload (a cell-killing drug such as a microtubule inhibitor or topoisomerase I inhibitor). After binding HER2, the ADC is typically internalized and processed so the payload can be released to damage critical cellular machinery and trigger cancer cell death; depending on the payload/linker properties, some HER2 ADCs can also produce a bystander effect, meaning the released payload may diffuse to kill nearby tumor cells that have lower HER2 expression.
HER2 Targeting ADC Drugs fuse the validated targeting precision of anti-HER2 antibodies with the tumor-killing power of highly potent payloads, offering a pragmatic way to overcome two persistent oncology pain points at once: the limited durability of benefit from many standard targeted agents once resistance emerges, and the systemic toxicity that often constrains conventional chemotherapy. By using HER2 as a delivery address, these conjugates can concentrate cytotoxic exposure inside cancer cells and—depending on linker and payload design—extend activity into heterogeneous tumors through bystander killing, which is increasingly important as clinicians recognize that clinically meaningful HER2 biology exists beyond the classic “HER2-positive” bucket. Looking forward, the category’s market potential is supported by broad applicability across major solid tumors, steady innovation that improves therapeutic index through smarter linkers, controlled conjugation, and next-generation payloads, and the likelihood that HER2 ADCs will become central “backbone” options that can be sequenced with, or paired alongside, endocrine therapy, immunotherapy, and other targeted agents—positioning the space for sustained expansion without relying on unrealistic expectations.
The core raw materials for HER2 Targeting ADC Drugs mainly include anti-HER2 antibodies, linkers, and auxiliary materials. Typical suppliers include Roche, Daiichi Sankyo, Merck, Thermo Fisher, etc. The downstream applications are mainly in the treatment of diseases such as breast cancer.
The production capacity of HER2 Targeting ADC Drugs varies greatly depending on the antibody production, conjugation process, quality control, and supply chain support. The gross profit margin of HER2 Targeting ADC Drugs is in the range of 70%-80%.
This report is a detailed and comprehensive analysis for global HER2 Targeting ADC Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global HER2 Targeting ADC Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global HER2 Targeting ADC Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global HER2 Targeting ADC Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global HER2 Targeting ADC Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for HER2 Targeting ADC Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global HER2 Targeting ADC Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, AstraZeneca, Daiichi Sankyo, Remegen, Jiangsu Hengrui Medicine, Shanghai Henlius Biotech, Sichuan Kelun-Biotech Biopharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
HER2 Targeting ADC Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Trastuzumab Type
Non-trastuzumab Type
Market segment by HER2 Expression Level
HER2 Positive
HER2 Low Expression
Market segment by Antibody
Monoclonal Antibody
Bispecific Antibody
Others
Market segment by Application
Breast Cancer
Others
Major players covered
Roche
AstraZeneca
Daiichi Sankyo
Remegen
Jiangsu Hengrui Medicine
Shanghai Henlius Biotech
Sichuan Kelun-Biotech Biopharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe HER2 Targeting ADC Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of HER2 Targeting ADC Drugs, with price, sales quantity, revenue, and global market share of HER2 Targeting ADC Drugs from 2021 to 2026.
Chapter 3, the HER2 Targeting ADC Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the HER2 Targeting ADC Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and HER2 Targeting ADC Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of HER2 Targeting ADC Drugs.
Chapter 14 and 15, to describe HER2 Targeting ADC Drugs sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global HER2 Targeting ADC Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Trastuzumab Type
    • 1.3.3 Non-trastuzumab Type
  • 1.4 Market Analysis by HER2 Expression Level
    • 1.4.1 Overview: Global HER2 Targeting ADC Drugs Consumption Value by HER2 Expression Level: 2021 Versus 2025 Versus 2032
    • 1.4.2 HER2 Positive
    • 1.4.3 HER2 Low Expression
  • 1.5 Market Analysis by Antibody
    • 1.5.1 Overview: Global HER2 Targeting ADC Drugs Consumption Value by Antibody: 2021 Versus 2025 Versus 2032
    • 1.5.2 Monoclonal Antibody
    • 1.5.3 Bispecific Antibody
    • 1.5.4 Others
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global HER2 Targeting ADC Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Breast Cancer
    • 1.6.3 Others
  • 1.7 Global HER2 Targeting ADC Drugs Market Size & Forecast
    • 1.7.1 Global HER2 Targeting ADC Drugs Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global HER2 Targeting ADC Drugs Sales Quantity (2021-2032)
    • 1.7.3 Global HER2 Targeting ADC Drugs Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche HER2 Targeting ADC Drugs Product and Services
    • 2.1.4 Roche HER2 Targeting ADC Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Recent Developments/Updates
  • 2.2 AstraZeneca
    • 2.2.1 AstraZeneca Details
    • 2.2.2 AstraZeneca Major Business
    • 2.2.3 AstraZeneca HER2 Targeting ADC Drugs Product and Services
    • 2.2.4 AstraZeneca HER2 Targeting ADC Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 AstraZeneca Recent Developments/Updates
  • 2.3 Daiichi Sankyo
    • 2.3.1 Daiichi Sankyo Details
    • 2.3.2 Daiichi Sankyo Major Business
    • 2.3.3 Daiichi Sankyo HER2 Targeting ADC Drugs Product and Services
    • 2.3.4 Daiichi Sankyo HER2 Targeting ADC Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Daiichi Sankyo Recent Developments/Updates
  • 2.4 Remegen
    • 2.4.1 Remegen Details
    • 2.4.2 Remegen Major Business
    • 2.4.3 Remegen HER2 Targeting ADC Drugs Product and Services
    • 2.4.4 Remegen HER2 Targeting ADC Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Remegen Recent Developments/Updates
  • 2.5 Jiangsu Hengrui Medicine
    • 2.5.1 Jiangsu Hengrui Medicine Details
    • 2.5.2 Jiangsu Hengrui Medicine Major Business
    • 2.5.3 Jiangsu Hengrui Medicine HER2 Targeting ADC Drugs Product and Services
    • 2.5.4 Jiangsu Hengrui Medicine HER2 Targeting ADC Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Jiangsu Hengrui Medicine Recent Developments/Updates
  • 2.6 Shanghai Henlius Biotech
    • 2.6.1 Shanghai Henlius Biotech Details
    • 2.6.2 Shanghai Henlius Biotech Major Business
    • 2.6.3 Shanghai Henlius Biotech HER2 Targeting ADC Drugs Product and Services
    • 2.6.4 Shanghai Henlius Biotech HER2 Targeting ADC Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Shanghai Henlius Biotech Recent Developments/Updates
  • 2.7 Sichuan Kelun-Biotech Biopharmaceutical
    • 2.7.1 Sichuan Kelun-Biotech Biopharmaceutical Details
    • 2.7.2 Sichuan Kelun-Biotech Biopharmaceutical Major Business
    • 2.7.3 Sichuan Kelun-Biotech Biopharmaceutical HER2 Targeting ADC Drugs Product and Services
    • 2.7.4 Sichuan Kelun-Biotech Biopharmaceutical HER2 Targeting ADC Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Sichuan Kelun-Biotech Biopharmaceutical Recent Developments/Updates

3 Competitive Environment: HER2 Targeting ADC Drugs by Manufacturer

  • 3.1 Global HER2 Targeting ADC Drugs Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global HER2 Targeting ADC Drugs Revenue by Manufacturer (2021-2026)
  • 3.3 Global HER2 Targeting ADC Drugs Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of HER2 Targeting ADC Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 HER2 Targeting ADC Drugs Manufacturer Market Share in 2025
    • 3.4.3 Top 6 HER2 Targeting ADC Drugs Manufacturer Market Share in 2025
  • 3.5 HER2 Targeting ADC Drugs Market: Overall Company Footprint Analysis
    • 3.5.1 HER2 Targeting ADC Drugs Market: Region Footprint
    • 3.5.2 HER2 Targeting ADC Drugs Market: Company Product Type Footprint
    • 3.5.3 HER2 Targeting ADC Drugs Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global HER2 Targeting ADC Drugs Market Size by Region
    • 4.1.1 Global HER2 Targeting ADC Drugs Sales Quantity by Region (2021-2032)
    • 4.1.2 Global HER2 Targeting ADC Drugs Consumption Value by Region (2021-2032)
    • 4.1.3 Global HER2 Targeting ADC Drugs Average Price by Region (2021-2032)
  • 4.2 North America HER2 Targeting ADC Drugs Consumption Value (2021-2032)
  • 4.3 Europe HER2 Targeting ADC Drugs Consumption Value (2021-2032)
  • 4.4 Asia-Pacific HER2 Targeting ADC Drugs Consumption Value (2021-2032)
  • 4.5 South America HER2 Targeting ADC Drugs Consumption Value (2021-2032)
  • 4.6 Middle East & Africa HER2 Targeting ADC Drugs Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global HER2 Targeting ADC Drugs Sales Quantity by Type (2021-2032)
  • 5.2 Global HER2 Targeting ADC Drugs Consumption Value by Type (2021-2032)
  • 5.3 Global HER2 Targeting ADC Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global HER2 Targeting ADC Drugs Sales Quantity by Application (2021-2032)
  • 6.2 Global HER2 Targeting ADC Drugs Consumption Value by Application (2021-2032)
  • 6.3 Global HER2 Targeting ADC Drugs Average Price by Application (2021-2032)

7 North America

  • 7.1 North America HER2 Targeting ADC Drugs Sales Quantity by Type (2021-2032)
  • 7.2 North America HER2 Targeting ADC Drugs Sales Quantity by Application (2021-2032)
  • 7.3 North America HER2 Targeting ADC Drugs Market Size by Country
    • 7.3.1 North America HER2 Targeting ADC Drugs Sales Quantity by Country (2021-2032)
    • 7.3.2 North America HER2 Targeting ADC Drugs Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe HER2 Targeting ADC Drugs Sales Quantity by Type (2021-2032)
  • 8.2 Europe HER2 Targeting ADC Drugs Sales Quantity by Application (2021-2032)
  • 8.3 Europe HER2 Targeting ADC Drugs Market Size by Country
    • 8.3.1 Europe HER2 Targeting ADC Drugs Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe HER2 Targeting ADC Drugs Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific HER2 Targeting ADC Drugs Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific HER2 Targeting ADC Drugs Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific HER2 Targeting ADC Drugs Market Size by Region
    • 9.3.1 Asia-Pacific HER2 Targeting ADC Drugs Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific HER2 Targeting ADC Drugs Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America HER2 Targeting ADC Drugs Sales Quantity by Type (2021-2032)
  • 10.2 South America HER2 Targeting ADC Drugs Sales Quantity by Application (2021-2032)
  • 10.3 South America HER2 Targeting ADC Drugs Market Size by Country
    • 10.3.1 South America HER2 Targeting ADC Drugs Sales Quantity by Country (2021-2032)
    • 10.3.2 South America HER2 Targeting ADC Drugs Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa HER2 Targeting ADC Drugs Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa HER2 Targeting ADC Drugs Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa HER2 Targeting ADC Drugs Market Size by Country
    • 11.3.1 Middle East & Africa HER2 Targeting ADC Drugs Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa HER2 Targeting ADC Drugs Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 HER2 Targeting ADC Drugs Market Drivers
  • 12.2 HER2 Targeting ADC Drugs Market Restraints
  • 12.3 HER2 Targeting ADC Drugs Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of HER2 Targeting ADC Drugs and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of HER2 Targeting ADC Drugs
  • 13.3 HER2 Targeting ADC Drugs Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 HER2 Targeting ADC Drugs Typical Distributors
  • 14.3 HER2 Targeting ADC Drugs Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on HER2 Targeting ADC Drugs. Industry analysis & Market Report on HER2 Targeting ADC Drugs is a syndicated market report, published as Global HER2 Targeting ADC Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of HER2 Targeting ADC Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo